Why the study?
Does TCV-116 reduce renal arterial wall dimensions in spontaneously hypertensive rats?
Does TCV-116 reduce renal arterial wall dimensions in spontaneously hypertensive rats?
Answers are grounded in this paper and cite their sources.
Angiotensin II antagonism reduces systemic blood pressure and left ventricular hypertrophy but does not prevent intra-renal arterial wall hypertrophy in spontaneously hypertensive rats.
The effects of the angiotensin II type 1 receptor antagonist TCV-116 on the wall dimensions of the interlobular and arcuate arteries have been studied. SHR rats were treated with TCV-116 between 4 and 10 weeks, at which time their kidneys were perfusion-fixed and examined using stereological techniques. TCV-116 reduced arterial pressure and left ventricle/body weight ratio, but did not reduce renal arterial wall dimensions. For both arcuate and interlobular arteries, wall density/kidney ratio was significantly greater in the TCV-116 treated SHR than in untreated SHR and wall:lumen ratio was also significantly greater for the interlobular arteries in the TCV-116 treated rats. These findings are similar to those obtained previously using enalapril, and indicate that hypertrophy of the walls of these intra-renal arteries is not secondary to the elevated arterial pressure, unlike in other vascular beds.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: